BMO Capital Initiates Coverage of Privia Health Group (PRVA) with Outperform Recommendation
BMO Capital Markets has initiated coverage on Privia Health Group (PRVA) with an "Outperform" rating. This new coverage suggests a positive outlook from the firm regarding Privia Health's stock performance. Investors and market watchers will likely monitor PRVA's performance following this recommendation.
Privia Health Group CEO & Director Parth Mehrotra Sells 47% Of Holding
Parth Mehrotra, CEO & Director of Privia Health Group, recently sold shares worth US$2.7 million, reducing his holding by 47%. This was the largest insider sale within the last year, suggesting insiders might view lower prices as reasonable, although the company is profitable and growing. While insider selling can be a weak negative signal, Mehrotra still retains a significant stake, and insiders collectively own about 0.6% of the company.
Insider Selling: Privia Health Group (NASDAQ:PRVA) CEO Sells 105,439 Shares of Stock
Privia Health Group CEO Parth Mehrotra sold 105,439 shares of company stock for approximately $2.38 million on May 11th, reducing his direct ownership by 18.98%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, was primarily to cover tax withholding obligations from vesting equity awards. Despite other recent insider sales by Mehrotra, analysts maintain a "Moderate Buy" rating for PRVA, with a consensus target price of $31.23, following strong Q1 earnings that surpassed expectations.
Privia Health Group (NASDAQ:PRVA) CFO Sells $76,501.00 in Stock
Privia Health Group CFO David Mountcastle sold 3,385 shares of PRVA stock for approximately $76,501 on May 11th, primarily to cover tax withholding obligations from vested equity awards. This sale reduced his stake by 1.58%, although he still holds 211,462 shares valued at over $4.7 million. The company recently exceeded quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" consensus rating with a target price above current trading levels.
Privia Health Group (Nasdaq:PRVA) - Stock Analysis
Privia Health Group (NASDAQ:PRVA) is a national physician-enablement company with a market cap of US$2.9 billion, currently trading 42% below its estimated fair value. Analysts forecast a 32.52% annual earnings growth, supported by expansion into new markets and growing value-based care. Recent insider selling and a Q1 2026 EPS miss, despite revenue growth, present some headwinds for the company.
Privia Health Group's (NASDAQ:PRVA) Earnings May Just Be The Starting Point
Privia Health Group (NASDAQ:PRVA) reported strong earnings, yet investors seemed underwhelmed. Analysis of the accrual ratio, which measures how well profit is backed by free cash flow, revealed a negative ratio of -0.37, indicating that statutory earnings were significantly less than free cash flow. This suggests the company's underlying earnings potential might be better than reported profits suggest, with EPS also up 22% annually over the last three years.
Privia Health Group's (NASDAQ:PRVA) Earnings May Just Be The Starting Point
Privia Health Group (NASDAQ:PRVA) posted strong earnings, but investors seemed underwhelmed. Analysis of the accrual ratio from cash flow, which indicates how well profit is backed by free cash flow, suggests the company's underlying earnings potential is better than its statutory profit. The negative accrual ratio of -0.37 and significant free cash flow of US$138m compared to US$21.8m in profit indicate strong conversion, alongside a 22% annual EPS growth over three years.
Privia Health Group Insider Sold Shares Worth $2,731,898, According to a Recent SEC Filing
An insider at Privia Health Group sold shares valued at $2,731,898, as reported in a recent SEC filing. The article, published on May 14, 2026, details this transaction along with recent company news, including Q1 2026 earnings results and financial guidance. Privia Health Group is a technology-driven physician-enablement company with a focus on enhancing physician practices and improving patient experiences.
[Form 4] Privia Health Group, Inc. Insider Trading Activity
Privia Health Group, Inc. CEO Parth Mehrotra reported open-market sales of 121,086 shares of company common stock over May 11-12, under a Rule 10b5-1 trading plan. The sales, at weighted average prices of $22.55 and $22.64, included shares sold to cover tax withholding on vested restricted stock units. After these transactions, Mehrotra directly holds 434,357 shares of Privia Health Group common stock.
Privia Health (PRVA) CFO tax-driven sale of 3,385 shares disclosed
Privia Health's CFO, David Mountcastle, reported a "sell to cover" transaction involving 3,385 shares of common stock at $22.60 per share. This nondiscretionary sale was performed to satisfy tax withholding obligations related to the vesting of restricted stock units. After the sale, Mountcastle directly holds 211,462 shares and indirectly owns 8,695 shares through his spouse.
Earnings call transcript: Privia Health Q1 2026 misses EPS but beats revenue
Privia Health Group Inc. reported mixed financial results for Q1 2026, missing EPS expectations with $0.02 against a forecast of $0.0746, while beating revenue projections with $603.85 million against an expected $559.49 million. The market reacted negatively, leading to a stock price decline post-earnings. Despite strong revenue growth and increased adjusted EBITDA, profitability concerns persist, although the company maintains a robust cash position and projects continued growth with an adjusted EBITDA of approximately $150 million for the full year 2026.
[144] Privia Health Group, Inc. SEC Filing
This SEC filing details a Form 144 notice from Parth Mehrotra of Privia Health Group, Inc. (PRVA) regarding the proposed sale of 15,647 shares tied to restricted stock vesting on May 9, 2026. The filing also reports several past dispositions of shares between March and May 2026, including a large sale on May 11, 2026, which generated over $2.3 million in proceeds. Fidelity Brokerage Services LLC is listed as the broker involved in these transactions.
A Look At Privia Health Group (PRVA) Valuation After Mixed Recent Share Performance
Privia Health Group (PRVA) has experienced mixed share performance recently, with a slight dip over the past week but a modest gain over the month, and a notable decline over the past year. Despite analysts suggesting it's undervalued with a narrative fair value of $31.80 against its closing price of $22.76, its high P/E ratio of 131.8x raises concerns about valuation risk. The company's growth is tied to the shift towards value-based care and its ability to manage operational costs.
[144] Privia Health Group, Inc. SEC Filing
Privia Health Group, Inc. (PRVA) filed a Form 144 to report the proposed sale of 14,036 shares of common stock through restricted stock vesting by the issuer on May 8, 2026. The filing also detailed previous common stock sales by Parth Mehrotra in March 2026, totaling several transactions with reported gross proceeds. Analysts indicate a neutral impact, viewing Rule 144 notices as administrative disclosures for proposed sales of restricted securities.
Privia Health Group, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PRVA)
Privia Health Group, Inc. (NASDAQ: PRVA) released its Q1 2026 earnings, reporting an EPS of $0.19, missing estimates by $0.06, and revenue of $603.85 million, beating by $41.92 million with a 25.78% year-over-year increase. The article provides access to the slide deck published in conjunction with their earnings call.
Privia Health Group Q1 Earnings Call Highlights
Privia Health Group reported strong first-quarter results, driven by double-digit provider growth and an expanded value-based care population, leading to a 36.3% rise in Adjusted EBITDA. Despite this performance, the company largely maintained its full-year guidance, only raising its outlook for year-end attributed lives. Executives also discussed their strategy for Medicare Advantage, commercial risk, Medicaid, and leveraging AI for margin expansion, while emphasizing a focus on business development and acquisitions.
Privia Health Group, Inc. (NASDAQ:PRVA) Q1 2026 Earnings Call Transcript
Privia Health Group, Inc. reported a strong Q1 2026, with revenue growth and increased provider and attributed lives. The company maintains its annual guidance, except for raising the outlook on attributed lives, confident in its operational execution and diversified business model. Privia Health continues to focus on expanding its national footprint, both organically and through strategic acquisitions, leveraging its strong balance sheet and prioritizing sustainable earnings growth through shared risk models.
Privia Health Group Q1 Profit Squeeze Tests Bullish High P E Narrative
Privia Health Group reported Q1 2026 revenue of US$603.8 million and net income of US$3.1 million, resulting in basic EPS of US$0.02. Despite trailing twelve-month earnings growth of 59.3%, the company's thin 1.1% net profit margin and high P/E ratio of 131.5x raise concerns about the sustainability of its valuation, particularly against an industry average of 25.2x. The article highlights the tension between bullish expectations of market expansion and value-based care, and the risks associated with a low-margin model in a consolidating healthcare industry.
Privia Health: Q1 Earnings Snapshot
Privia Health Group Inc. reported first-quarter net income of $3.1 million, or 2 cents per share, missing Wall Street expectations of 8 cents per share. However, the company's revenue of $603.8 million surpassed forecasts. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Privia Health Group, Inc. 1Q 2026: Revenue $603.85M, EPS $0.02— 10-Q Summary
Privia Health Group, Inc. reported its first-quarter 2026 results, with revenue rising 25.8% year-over-year to $603.85 million, although net income and diluted EPS saw declines. The revenue growth was attributed to fee-for-service patient care, shared-savings arrangements, and an increase in attributed lives. The company also expanded its value-based care mix and made operational progress by entering Arizona and acquiring an ACO.
Privia Health (NASDAQ: PRVA) grows Q1 2026 revenue 25.8% to $603.8M
Privia Health (NASDAQ: PRVA) reported strong Q1 2026 financial results, with revenue increasing by 25.8% to $603.8 million, driven by higher fee-for-service patient care and value-based care revenue. The company saw improved operating leverage, with Care Margin rising to $128.7 million, Platform Contribution to $67.0 million, and Adjusted EBITDA to $36.7 million. Despite these gains, net income attributable to Privia Health declined to $3.1 million due to a higher effective tax rate and increased stock-based compensation.
Earnings Flash (PRVA) Privia Health Group, Inc. Posts Q1 Adjusted EPS $0.19 per Share, vs. FactSet Est of $0.24
Privia Health Group, Inc. (PRVA) reported Q1 adjusted EPS of $0.19 per share, falling short of the FactSet estimate of $0.24. This earnings flash indicates that the company's first-quarter performance on an adjusted earnings per share basis did not meet analyst expectations. The full article provides more details, including the official publication date and time.
Privia Health (NASDAQ:PRVA) Posts Better-Than-Expected Sales In Q1 CY2026
Privia Health (NASDAQ:PRVA) reported better-than-expected Q1 CY2026 revenue of $603.8 million, a 25.8% year-over-year increase, exceeding analyst estimates. However, its non-GAAP profit per share of $0.19 missed consensus estimates by 24.1%. The company reaffirmed its full-year revenue guidance of $2.4 billion and provided EBITDA guidance in line with expectations, leading to a mixed reaction from the market.
Privia Health (Nasdaq: PRVA) posts 25.8% Q1 revenue growth and raises lives outlook
Privia Health (Nasdaq: PRVA) reported significant Q1 2026 growth with total revenue increasing by 25.8% to $603.8 million and Adjusted EBITDA up 36.3% to $36.7 million. Despite a decline in GAAP net income due to higher non-cash stock compensation, key operating metrics like implemented providers and attributed lives saw substantial growth. The company reiterated its full-year 2026 guidance for revenue and Adjusted EBITDA, while raising its outlook for Attributed Lives, demonstrating confidence in its value-based care model.
Earnings Flash (PRVA) Privia Health Group, Inc. Reports Q1 Revenue $603.8M, vs. FactSet Est of $561.0M
Privia Health Group, Inc. (PRVA) announced its Q1 revenue reached $603.8 million, significantly surpassing the FactSet estimate of $561.0 million. The company also reaffirmed its 2026 revenue guidance, expecting it to be between $2.35 billion and $2.45 billion, aligning with analyst expectations. This financial update highlights Privia Health's strong performance in the first quarter.
Privia Health: Q1 Earnings Snapshot
Privia Health Group Inc. reported first-quarter net income of $3.1 million, or 2 cents per share, missing analyst expectations of 8 cents per share. However, the physician practice management company's revenue of $603.8 million surpassed Street forecasts of $560 million. This data was generated by Automated Insights using information from Zacks Investment Research.
Privia now expects up to 1.625M covered lives in 2026
Privia Health (NASDAQ: PRVA) reported its Q1 2026 financial results, with revenue increasing by 25.8% year-over-year to $603.8 million and adjusted EBITDA up 36.3% to $36.7 million. The company raised its full-year 2026 guidance for attributed lives to a range of 1.600 million to 1.625 million, while reiterating other financial forecasts. GAAP net income, however, declined to $3.1 million, impacted by non-cash stock compensation.
Privia Health earnings on deck as analysts eye provider expansion
Privia Health (NASDAQ:PRVA) is set to report its first-quarter earnings, with analysts expecting $0.07 EPS and $559.5 million in revenue, a sequential increase from the previous quarter. The company, rated a Strong Buy by analysts, is being watched for its geographic expansion, provider conversion, and strong cash generation as key indicators for its value-based care model. Its previous quarter's strong performance has fueled optimism, and investors will look for continued momentum in a growing healthcare segment.
What to expect from Privia Health’s (PRVA) Q1 earnings
This article forecasts the Q1 2026 earnings for Privia Health (PRVA), with analysts expecting a year-over-year increase in earnings and revenue. The report highlights the consensus EPS and revenue estimates, the stock's performance leading up to the earnings call, and recent analyst rating changes.
Privia Health director Morris sells $452k in stock
Matthew Shawn Morris, a director at Privia Health Group, Inc. (NASDAQ:PRVA), recently sold 18,113 shares of company stock across two transactions on May 1 and May 4, 2026, totaling $452,613. These sales were conducted under a Rule 10b5-1 trading plan shortly after he acquired the same number of shares through the exercise of stock options. Despite the insider selling, analyst sentiment for Privia Health remains positive with several firms raising price targets and maintaining strong ratings.
What to expect from Privia Health’s (PRVA) Q1 earnings
This article provides an analysis of Privia Health's upcoming Q1 2026 earnings report. It highlights analyst expectations for revenue and EPS, notes the company's past earnings performance, and mentions recent analyst rating changes, setting the stage for what investors should look for in the announcement.
Privia Health CFO David Mountcastle sells $209,840 in stock
David Mountcastle, CFO of Privia Health Group, Inc. (NASDAQ:PRVA), recently sold shares totaling approximately $209,840 after exercising stock options. These transactions, executed under a Rule 10b5-1 trading plan, occurred between May 1 and May 4, 2026, with sales prices ranging from $25.00 to $25.03 per share. The company is nearing its earnings report and has received positive analyst outlooks, with several firms raising price targets.
Privia Health Group (PRVA) CFO exercises options and sells 8,385 shares
Privia Health Group's EVP & CFO, David Mountcastle, exercised 8,385 stock options at $2.00 per share and subsequently sold the same number of common shares at approximately $25 per share on May 1 and May 4, 2026. These transactions, valued at around $210,000, were conducted under a pre-adopted Rule 10b5-1 trading plan. Following these sales, Mountcastle retains a substantial equity stake, directly owning 214,847 common shares and indirectly 8,695 shares through his spouse.
Privia Health director Morris sells $452k in stock
Matthew Shawn Morris, a Director at Privia Health Group, Inc. (NASDAQ:PRVA), sold 18,113 shares of company stock across two transactions on May 1 and May 4, 2026, totaling $452,613. These sales followed the exercise of stock options for the same number of shares at a significantly lower price. Despite the sales, Morris retains a substantial direct and indirect holding in the company, while Privia Health has recently received positive ratings and price target increases from several analysts following strong financial performance.
Privia Health (PRVA) director exercises options and sells 18,113 shares under 10b5-1 plan
Matthew Shawn Morris, a director at Privia Health Group, Inc. (PRVA), exercised stock options for 18,113 shares and subsequently sold them in open-market transactions on May 1 and May 4, 2026, for approximately $24.99 and $24.96 per share, respectively. These transactions were carried out under a Rule 10b5-1 trading plan. Following these sales, Morris retains significant direct and indirect holdings, along with a substantial number of remaining stock options.
Multiple insider share sales reported for PRVA (NASDAQ: PRVA)
Privia Health Group, Inc. (NASDAQ: PRVA) has reported multiple proposed insider sales through a Form 144 notice. The filing details planned cash sales of common shares, including those derived from options granted between 2018 and 2020, and also lists actual open-market dispositions by a reported holder, David Mountcastle, on various dates in 2026.
Behavioral Patterns of PRVA and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Privia Health Group Inc. (NASDAQ: PRVA) using AI models. It highlights strong near and mid-term positive sentiment, an exceptional short setup with a 34.4:1 risk-reward ratio, and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop-loss zones. The analysis also provides multi-timeframe signal strength, support, and resistance levels for PRVA.
PRVA (PRVA) director sells shares across Feb–Apr 2026, Form 144 shows amounts
A Form 144 filing indicates that David Mountcastle, a director at Privia Health Group, Inc. (PRVA), sold multiple tranches of common stock between February and April 2026. The sales included transactions like 5,361 shares for $134,030.87 on February 26, 2026, and 7,697 shares for $192,798.08 on February 27, 2026. The filing also details options granted on various dates that were converted to cash on May 1, 2026, and lists Fidelity Brokerage Services LLC as the broker.
PRVA (NASDAQ: PRVA) insider sells 16,550 shares for $413,745 reported
An insider at Privia Health Group, Inc. (NASDAQ: PRVA) registered proposed sales of common stock, with a Form 144 filing detailing two dispositions. The filing reports the sale of 7,788 shares on February 26, 2026, and 16,550 shares on February 27, 2026, with the latter generating proceeds of $413,745.04. The shares were acquired as compensation in the form of Restricted Stock Units initially granted in 2018.
Analysts Offer Insights on Healthcare Companies: Humana (HUM) and Teladoc (TDOC)
Analysts have issued neutral ratings for healthcare companies Humana (HUM) and Teladoc (TDOC), indicating a balanced outlook on the stocks. KeyBanc maintained a Hold rating on Humana, with Bank of America Securities reiterating the same, while Citi assigned a Hold rating to Teladoc, and William Blair also maintained a Hold. Both companies received average price targets suggesting either a slight downside for Humana or a moderate upside for Teladoc.
Analysts Offer Insights on Healthcare Companies: Humana (HUM) and Teladoc (TDOC)
This article summarizes recent analyst ratings for healthcare companies Humana (HUM) and Teladoc (TDOC). Analysts from KeyBanc and Bank of America Securities maintained "Hold" ratings for Humana, predicting a slight downside from current levels. Citi and William Blair also assigned "Hold" ratings to Teladoc, despite a general "Moderate Buy" consensus suggesting a potential upside.
Privia Health Group (PRVA) to Release Quarterly Earnings on Thursday
Privia Health Group (PRVA) is set to announce its Q1 2026 earnings before the market opens on Thursday, May 7th, with analysts expecting $0.08 EPS and $559.516 million in revenue. The company previously surpassed expectations in Q4, reporting $0.25 EPS against a $0.04 consensus. Wall Street sentiment is generally positive, with a "Moderate Buy" consensus rating and an average price target of $31.31.
Vanguard Portfolio Management (NASDAQ: PRVA) holds 6.38M shares (5.16%)
Vanguard Portfolio Management has reported a 5.16% beneficial ownership in Privia Health Group Inc. (NASDAQ: PRVA), amounting to 6,382,685 shares as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing specifies 101,143 shares with sole voting power and 6,382,685 shares with sole dispositive power, consistent with common institutional ownership practices for Vanguard funds and managed accounts.
Privia Health Group, Inc. (NASDAQ:PRVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Privia Health Group, Inc. (NASDAQ:PRVA) has received a "Moderate Buy" consensus rating from brokerages, with 11 analysts recommending a buy and 3 a hold. The average one-year price target is $31.31. The company recently surpassed earnings and revenue expectations, reporting $0.25 EPS against an estimated $0.04 and revenue of $541.17 million.
PRVA|Privia Health Group Inc|Price:24.690|Chg%:-0.15
Privia Health Group Inc (PRVA) shows strong fundamentals, high growth potential, and good ESG disclosure, ranking well within its industry. The stock is considered fairly valued with strong stock market performance over the last month, supported by analyst "Buy" ratings and a target price implying a 27.88% upside. The price is currently trading sideways, suggesting suitability for range-bound swing trading.
Stronger-Than-Expected Earnings and Guidance Could Be A Game Changer For Privia Health Group (PRVA)
Privia Health Group (PRVA) reported stronger-than-expected quarterly revenue and earnings, leading to raised full-year guidance. This positive news, highlighting improved profitability and an upgraded outlook, could significantly impact the company's investment narrative, moving past prior concerns about subscale operations. While supporting the thesis of profitable growth in the value-based care model, investors should still consider risks like future reimbursement terms and rising healthcare labor costs.
(PRVA) Movement Within Algorithmic Entry Frameworks
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA) using AI models, highlighting a strong near and mid-term sentiment that could extend long-term. It identifies an exceptional 34.6:1 risk-reward setup targeting a 10.5% gain versus 0.3% risk. The analysis provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels.
Tudor Investment Corp Trims Stake in Privia Health Group
Tudor Investment Corp ET AL has significantly reduced its stake in Privia Health Group (NASDAQ:PRVA) by 95.1% in the third quarter, selling 445,865 shares and retaining only 22,986 shares valued at $572,000. This move by the prominent hedge fund signals a potential shift in investor sentiment regarding the healthcare technology company's financial infrastructure and growth prospects. Despite this reduction, Privia Health Group, which partners with independent physicians, continues its work in managing population health and optimizing financial performance.
Tudor Investment Corp ET AL Sells 445,865 Shares of Privia Health Group, Inc. $PRVA
Tudor Investment Corp ET AL significantly reduced its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 95.1% in Q3, selling 445,865 shares and retaining 22,986 shares. Concurrently, company insiders, including CEO Parth Mehrotra, sold a substantial amount of stock. Despite these insider sales, Privia Health Group recently surpassed quarterly earnings and revenue estimates and holds a "Moderate Buy" consensus rating from analysts with an average target price of $31.31.
How (PRVA) Movements Inform Risk Allocation Models
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA) through AI models, highlighting strong near- and mid-term sentiment and a mid-channel oscillation pattern. It presents three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for PRVA.
